Your browser doesn't support javascript.
loading
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
Ali, Shaukat; Shalim, Elisha; Farhan, Farah; Anjum, Fatima; Ali, Ayesha; Uddin, Syed Muneeb; Shahab, Faisal; Haider, Mustafa; Ahmed, Iqra; Ali, Mir Rashid; Khan, Sadaf; Rao, Sadia; Guriro, Kabeer; Elahi, Saud; Ali, Muhammad; Mushtaq, Tehreem; Sayeed, Muneeba Ahsan; Muhaymin, Sheikh Muhammad; Luxmi, Shoba; Qureshi, Saeed.
Afiliação
  • Ali S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan. ali.shaukat@duhs.edu.pk.
  • Shalim E; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Farhan F; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
  • Anjum F; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali A; Dow Research Institute Of Bio-Technology And Bio-Sciences (DRIBBS), Dow University of Health Sciences, Karachi, Pakistan.
  • Uddin SM; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Shahab F; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Haider M; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ahmed I; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali MR; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Khan S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Rao S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Guriro K; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Elahi S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali M; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
  • Mushtaq T; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Sayeed MA; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Muhaymin SM; Sindh Infectious Disease Hospital and Research Center, Karachi, Pakistan.
  • Luxmi S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Saifullah; Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan.
  • Qureshi S; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
Trials ; 23(1): 932, 2022 Nov 08.
Article em En | MEDLINE | ID: mdl-36348476
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article